Eli Lilly to Build $4.5 Billion Research, Manufacturing Plant in Indiana

By Colin Kellaher

Eli Lilly will spend $4.5 billion to build a new plant in Indiana that combines research and manufacturing in a single location.

Lilly on Wednesday said the plant, dubbed the Lilly Medicine Foundry, is the first of its kind and will give the Indianapolis drugmaker the ability to research new ways of producing medicines while also scaling up manufacturing of drug for clinical trials for its growing pipeline.

Lilly said it will build to plant, slated to open in late 2027, in Indiana's LEAP Research & Innovation District in Lebanon, where the drug maker earlier this year unveiled plans to spend $5.3 billion to boost manufacturing capacity for its hot-selling anti-obesity drug Zepbound and cousin diabetes drug Mounjaro.

The company said the plant, which will create 400 full-time jobs, brings its investment in Lebanon to more than $13 billion and its total capital commitment in the U.S. to more than $23 billion since 2020.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 02, 2024 08:21 ET (12:21 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.